Assessment Status | NCPE Assessment Process Complete |
HTA ID | 21043 |
Drug | Nivolumab |
Brand | Opdivo® |
Indication | Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
Assessment Process | |
Rapid review commissioned | 21/09/2021 |
Rapid review completed | 20/10/2021 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 28/10/2021 |
Pre-submission consultation with Applicant | 20/12/2021 |
Full submission received from Applicant | 11/05/2022 |
Preliminary review sent to Applicant | 24/10/2022 |
NCPE assessment re-commenced | 21/11/2022 |
Factual accuracy sent to Applicant | 23/01/2023 |
NCPE assessment re-commenced | 30/01/2023 |
NCPE assessment completed | 13/02/2023 |
NCPE assessment outcome | The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.